Mintzer S, Skidmore CT, Abidin CJ, et al. Effects of antiepileptic drugs on lipids, homocysteine, and C-reactive protein. Ann Neurol. 2009;65:448–56.

Article  CAS  PubMed  Google Scholar 

Mintzer S, Skidmore CT, Rankin SJ, et al. Conversion from enzyme-inducing antiepileptic drugs to topiramate: effects on lipids and c-reactive protein. Epilepsy Res. 2012;98:88–93.

Article  CAS  PubMed  Google Scholar 

Mintzer S, Miller R, Shah K, et al. Long-term effect of antiepileptic drug switch on serum lipids and C-reactive protein. Epilepsy Behav. 2016;58:127–32.

Article  PubMed  PubMed Central  Google Scholar 

Mintzer S, Dimova S, Zhang Y, et al. Effects of lacosamide and carbamazepine on lipids in a randomized trial. Epilepsia. 2020;61:2696–704.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Garoufi A, Koemtzidou E, Katsarou E, et al. Lipid profile and thyroid hormone concentrations in children with epilepsy treated with oxcarbazepine monotherapy: a prospective long-term study. Eur J Neurol. 2014;21:118–23.

Article  CAS  PubMed  Google Scholar 

Isojarvi JI, Pakarinen AJ, Rautio A, Pelkonen O, Myllyla VV. Liver enzyme induction and serum lipid levels after replacement of carbamazepine with oxcarbazepine. Epilepsia. 1994;35:1217–20.

Article  CAS  PubMed  Google Scholar 

Kim DW, Lee SY, Shon YM, Kim JH. Effects of new antiepileptic drugs on circulatory markers for vascular risk in patients with newly diagnosed epilepsy. Epilepsia. 2013;54:e146–9.

Article  CAS  PubMed  Google Scholar 

Mintzer S, Wechsler RT, Rogin JB, et al. Effects of adjunctive eslicarbazepine acetate on serum lipids in patients with partial-onset seizures: impact of concomitant statins and enzyme-inducing antiepileptic drugs. Epilepsy Res. 2018;141:83–9.

Article  CAS  PubMed  Google Scholar 

Mintzer S, Mattson R. Should enzyme-inducing antiepileptic drugs be considered first-line agents? Epilepsia. 2009;50:42–50.

Article  CAS  PubMed  Google Scholar 

Lopinto-Khoury C, Mintzer S. Antiepileptic drugs and markers of vascular risk. Curr Treat Options Neurol. 2010;12:300–8.

Article  PubMed  PubMed Central  Google Scholar 

•• Josephson CB, Wiebe S, Delgado-Garcia G et al. Association of enzyme-inducing antiseizure drug use with long-term cardiovascular disease. JAMA Neurol. 2021;78:1367–1374. Best study done to date to establish that EIASMs appear to increase vascular disease risk.

• Lee-Lane E, Torabi F, Lacey A et al. Epilepsy, antiepileptic drugs, and the risk of major cardiovascular events. Epilepsia. 2021;62:1604–1616. Another study of EIASMs and vascular risk, reaching opposite conclusions from the above study, though it is probably not quite as strong methodologically.

Ucar M, Neuvonen M, Luurila H, Dahlqvist R, Neuvonen PJ, Mjorndal T. Carbamazepine markedly reduces serum concentrations of simvastatin and simvastatin acid. Eur J Clin Pharmacol. 2004;59:879–82.

Article  CAS  PubMed  Google Scholar 

Bullman J, Nicholls A, Van Landingham K, et al. Effects of lamotrigine and phenytoin on the pharmacokinetics of atorvastatin in healthy volunteers. Epilepsia. 2011;52:1351–8.

Article  CAS  PubMed  Google Scholar 

Wang SP, Mintzer S, Skidmore CT, et al. Seizure recurrence and remission after switching antiepileptic drugs. Epilepsia. 2013;54:187–93.

Article  CAS  PubMed  Google Scholar 

Finamore JM, Sperling MR, Zhan T, Nei M, Skidmore CT, Mintzer S. Seizure outcome after switching antiepileptic drugs: a matched, prospective study. Epilepsia. 2016;57:1294–300.

Article  CAS  PubMed  Google Scholar 

Fischer TL, Pieper JA, Graff DW, et al. Evaluation of potential losartan-phenytoin drug interactions in healthy volunteers. Clin Pharmacol Ther. 2002;72:238–46.

Article  CAS  PubMed  Google Scholar 

Rowan AJ, Veldhuisen RJ, Nagelkerke NJ. Comparative evaluation of sleep deprivation and sedated sleep EEGs as diagnostic aids in epilepsy. Electroencephalogr Clin Neurophysiol. 1982;54:357–64.

Article  CAS  PubMed  Google Scholar 

Sachdeo RC, Wasserstein A, Mesenbrink PJ, D’Souza J. Effects of oxcarbazepine on sodium concentration and water handling. Ann Neurol. 2002;51:613–20.

Article  CAS  PubMed  Google Scholar 

Lu X, Wang X. Hyponatremia induced by antiepileptic drugs in patients with epilepsy. Expert Opin Drug Saf. 2017;16:77–87.

Article  CAS  PubMed  Google Scholar 

Cropp JS, Bussey HI. A review of enzyme induction of warfarin metabolism with recommendations for patient management. Pharmacotherapy. 1997;17:917–28.

Article  CAS  PubMed  Google Scholar 

Clark NP, Hoang K, Delate T, Horn JR, Witt DM. Warfarin interaction with hepatic cytochrome P-450 enzyme-inducing anticonvulsants. Clin Appl Thromb Hemost. 2018;24:172–8.

Article  CAS  PubMed  Google Scholar 

Candeloro M, Carlin S, Shapiro MJ, Douketis JD. Drug-drug interactions between direct oral anticoagulants and anticonvulsants and clinical outcomes: a systematic review. Res Pract Thromb Haemost. 2023;7: 100137.

Article  PubMed  PubMed Central  Google Scholar 

Yadav R, Schrem E, Yadav V, Jayarangaiah A, Das S, Theetha KP. Lacosamide-related arrhythmias: a systematic analysis and review of the literature. Cureus. 2021;13: e20736.

PubMed  PubMed Central  Google Scholar 

• Ingleby-Talecki L, van Dijkman SC, Oosterholt SP et al. Cardiac sodium channel inhibition by lamotrigine: in vitro characterization and clinical implications. Clin Transl Sci. 2022;15:1978–1989. In vitro study showing effects of lamotrigine on cardiac conduction are modest.

•• Christensen J, Trabjerg BB, Dreier JW. Cardiac morbidity and mortality associated with the use of lamotrigine. Epilepsia. 2022;63:2371–2380. Population study showing no evidence of increased cardiac mortality with lamotrigine treatment.

•• Bunschoten JW, Husein N, Devinsky O et al. Sudden death and cardiac arrythmia with lamotrigine: a rapid systematic review. Neurology. 2022;98:e1748-e1760. Review of all studies of lamotrigine-induced EKG changes, essentially negative.